ZMAT2

Across TCGA pan-cancer cohorts, ZMAT2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ZMAT2 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZMAT2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZMAT2 expression acts as an unfavorable survival marker.

LUAD are the cancer types where ZMAT2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.213	0.676	.012	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

ZMAT2–LUAD (DFS)

Open the LUAD breakdown →